Keryx Biopharmaceuticals Receives Orphan Drug Designation For KRX-0401 (Perifosine) For The Treatment Of Neuroblastoma

Keryx Biopharmaceuticals Receives Orphan Drug Designation For KRX-0401 (Perifosine) For The Treatment Of Neuroblastoma
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.
Read more on BioresearchOnline

Study: Pharmacy Costs in Workers’ Comp Jump 6.5 Percent in 2009
Average wholesale drug price increases and higher drug utilization rates fuel the pharmacy cost increase.
Read more on Risk & Insurance